Come up with a name for your new list and we'll add to it:
Biosceptre International raised a round of funding on December 15, 2017. Investors include
Tuspark S & T.
Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7…